BMS-986278 (LPA1 Antagonist): Phase 3 ALOFT Trial for IPF

The Next Generation of Pulmonary Fibrosis Targets: What is LPA1?

Current standard-of-care therapies for Idiopathic Pulmonary Fibrosis (IPF)—such as nintedanib and pirfenidone—can slow disease progression but cannot entirely halt it or restore lost lung function. To address this severe unmet medical need, the race to develop "next-generation mechanisms" is intensely competitive worldwide.

Among these, one of the most promising targets currently advancing through Phase 3 clinical trials is the antagonist for Lysophosphatidic acid receptor 1 (LPA1).

📌 Lysophosphatidic Acid (LPA) and the Fibrosis Mechanism

LPA is a lipid mediator generated from cell membrane phospholipids. While it regulates various physiological functions in a healthy state, tissue injury and inflammation in the lungs cause a dramatic spike in LPA concentrations, particularly measurable in bronchoalveolar lavage fluid (BALF).

LPA binds to LPA receptors (primarily LPA1), which are G protein-coupled receptors (GPCRs), triggering a powerful pro-fibrotic cascade:

1. Fibroblast Recruitment and Differentiation: LPA drives the chemotaxis of fibroblasts to the site of injury and stimulates their differentiation into hyper-active, collagen-secreting myofibroblasts.
2. Vascular Leakage and Apoptosis: LPA signaling disrupts the barrier function of alveolar epithelial and endothelial cells, leading to increased vascular permeability. This exacerbates inflammation and cements the pro-fibrotic microenvironment (fibrotic niche).

LPA1 receptor antagonists exert their potent anti-fibrotic effects by selectively blocking this upstream cascade at the receptor level.

---

The Pipeline Frontrunner: Admilparant / BMS-986278 (Bristol Myers Squibb)

Leading the pack in the LPA1 antagonist class is the oral compound admilparant (BMS-986278), developed by Bristol Myers Squibb (BMS).

📊 Promising Results in Phase 2

In a Phase 2, placebo-controlled, randomized clinical trial, BMS-986278 was administered for 26 weeks to patients with IPF and Progressive Pulmonary Fibrosis (PPF). The trial yielded highly encouraging data (presented at conferences like ATS 2023):

• Attenuated Decline in FVC (Forced Vital Capacity): Compared to the placebo group, the BMS-986278 arm demonstrated a significantly reduced rate of FVC decline (a relative reduction of approximately 62%).
• Efficacy as an Add-On Therapy: Crucially, this positive effect was consistent even in a subgroup of patients receiving background standard-of-care (nintedanib or pirfenidone). This strongly suggests that BMS-986278 possesses an "add-on effect" and can complement existing mechanisms (contextualized in the broader anti-fibrotic combination context).
• Favorable Safety Profile: The compound demonstrated good tolerability without significant signals of blood toxicity or severe hepatotoxicity, which have plagued other historical compounds.

🚀 The Phase 3 "ALOFT Trial" Design and Outlook

BMS-986278 has now advanced into a massive global Phase 3 clinical trial program (The ALOFT Trials).

• Populations: Two parallel trials — ALOFT-IPF (NCT06003426) for IPF, and ALOFT-PPF (NCT06025578) for PPF (including ILDs associated with autoimmune diseases, chronic hypersensitivity pneumonitis, and unclassifiable progressive fibrosing ILDs).
• Primary Endpoint: The absolute change in FVC from baseline at Week 52.
• Primary Completion (estimated): ALOFT-IPF October 2026, ALOFT-PPF December 2027 (per ClinicalTrials.gov).
• Significance: The results of these trials will be the watershed moment determining whether BMS-986278 becomes a new cornerstone monotherapy or a powerful combination agent in the fibrotic disease armamentarium.

---

The Competitive Landscape: Positioning Against FDA-Approved Nerandomilast

The most important benchmark for admilparant (BMS-986278) is Nerandomilast (JASCAYD), a PDE4B inhibitor developed by Boehringer Ingelheim. Nerandomilast received FDA approval for IPF in October 2025 and for PPF in December 2025, becoming the first novel IPF therapy approved in over a decade. Regulatory reviews in the EU, UK, and Japan are expected to conclude in 2026.

• Nerandomilast / JASCAYD (PDE4B Inhibitor): Now FDA-approved, it possesses a broader mechanism characterized by dual anti-inflammatory and anti-fibrotic actions. (See our Nerandomilast deep-dive and IPF Landscape article for details).
• Admilparant / BMS-986278 (LPA1 Antagonist): Currently in Phase 3 (ALOFT trials). Holds FDA Breakthrough Therapy Designation for PPF (October 2023), plus Fast Track and Orphan Drug Designations for IPF — stacking multiple regulatory incentives. Offers a highly targeted approach specifically blocking lipid mediator-driven fibroblast activation.

With nerandomilast now on the market, the landscape has fundamentally shifted. The key question is whether admilparant will be positioned as a combination partner alongside nerandomilast, or as an alternative option based on tolerability profiles (e.g., GI side effects) and patient phenotypes.

---

Evaluating LPA1 Antagonists in Preclinical Models

To accurately evaluate the efficacy of LPA1 antagonists like admilparant (BMS-986278) in the preclinical phase, robust animal models and rigorous study designs are essential.

1. Bleomycin-Induced Pulmonary Fibrosis Model: While this is the standard model, modern translational research mandates a "Therapeutic Dosing" design. Instead of prophylactic dosing before injury, the test article should be administered after fibrosis is established (typically Days 14 to 28) to demonstrate an arrest or reversal in FVC decline and Ashcroft Scores.
2. Biomarker Interrogation: Beyond standard collagen quantification (Hydroxyproline), measuring LPA levels in BALF/plasma and evaluating downstream signaling inhibition (such as the ROCK pathway and TGF-β/Smad downstream readouts) are crucial for validating the Mechanism of Action (MoA).

Related Preclinical Models

Explore our Pulmonary Fibrosis Models — Bleomycin, Silica & TGF-β1 protocols for IPF translation.

---

FAQ

Q1. Admilparant (BMS-986278) vs nerandomilast — how do these IPF therapies differ mechanistically and in market timing?

Admilparant (BMS-986278) is a selective LPA1 receptor antagonist that blocks lysophosphatidic acid signaling at the upstream lipid mediator level, suppressing fibroblast chemotaxis and myofibroblast differentiation. Nerandomilast (BI 1015550) is a PDE4B inhibitor producing dual anti-inflammatory and anti-fibrotic effects via the cAMP/PKA pathway. Nerandomilast received FDA approval for IPF on October 7, 2025; admilparant has Phase 3 ALOFT-IPF Primary Completion estimated October 2026. For full mechanistic and clinical comparison, see the nerandomilast PDE4B inhibitor profile and the IPF Treatment Landscape 2026.

Q2. Will admilparant be approved as monotherapy or as add-on to nintedanib/pirfenidone?

Admilparant is being positioned to support both pathways. The Phase 2 trial showed FVC decline reduction was consistent in subgroups receiving background nintedanib or pirfenidone, demonstrating an add-on effect on top of standard of care. The Phase 3 ALOFT trials enroll patients with and without background therapy, allowing labeling for both monotherapy and combination use. The likely commercial position is as a combination partner with nerandomilast or existing antifibrotics, given the orthogonal mechanism. See the anti-fibrotic drug hub and the next-generation antifibrotic pipeline for the full combination landscape.

Q3. How does the LPA1 antagonist tolerability profile compare with PDE4B inhibitor GI side effects?

Admilparant Phase 2 data showed favorable tolerability with no significant signals of blood toxicity or severe hepatotoxicity that have plagued earlier LPA1 candidates such as BMS-986020. Nerandomilast's most frequent adverse event is diarrhea, occurring in approximately 41% of patients, although most cases are mild to moderate. The differential GI tolerability suggests admilparant may serve patients who cannot tolerate PDE4B-class GI side effects, while remaining viable as a combination agent. Detailed AE profile in the nerandomilast PDE4B inhibitor profile.

Q4. When will ALOFT-IPF and ALOFT-PPF readout, and what FVC delta would constitute clinical success?

ALOFT-IPF (NCT06003426) has Primary Completion estimated October 2026, and ALOFT-PPF (NCT06025578) has December 2027, per ClinicalTrials.gov. The primary endpoint is the absolute change in FVC from baseline at Week 52. The Phase 2 benchmark of approximately 62% relative reduction in FVC decline versus placebo sets the success threshold; replication of this magnitude in Phase 3 would position admilparant as a class-defining LPA1 antagonist. ATS 2026 abstracts may signal interim trends — see the ATS 2026 IPF/PPF preview.

Q5. How should LPA1 antagonists be evaluated preclinically — bleomycin therapeutic dosing, BALF LPA, and biomarker selection?

Bleomycin-induced pulmonary fibrosis remains the standard model, but LPA1 antagonists require a therapeutic dosing design (administration on Days 14–28, after fibrosis is established) to demonstrate translational value beyond prophylactic effects. BALF LPA quantification confirms target engagement, while hydroxyproline content, Ashcroft scoring, and downstream Smad/ROCK readouts characterize the antifibrotic response. For protocol-level guidance, see the bleomycin model therapeutic dosing protocol, the IPF serum biomarker panel, and the TGF-β/Smad pathway primer.

References

1. Corte TJ, et al. Efficacy and Safety of Admilparant, an LPA(1) Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025;211(2):230-238. (PubMed) — peer-reviewed publication. Topline also reported in the Bristol Myers Squibb ATS 2023 press release.

2. ClinicalTrials.gov. ALOFT-IPF: BMS-986278 Phase 3 Study in IPF (NCT06003426) / ALOFT-PPF (NCT06025578)